Grootjans J, Lenaerts K, Buurman WA, Dejong CHC, Derikx JPM. Life and death at the mucosal-luminal interface: New perspectives on human intestinal ischemia-reperfusion. World J Gastroenterol 2016; 22(9): 2760-2770 [PMID: 26973414 DOI: 10.3748/wjg.v22.i9.2760]
Corresponding Author of This Article
Joep Grootjans, MD, PhD, Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands. j.grootjans@maastrichtuniversity.nl
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 7, 2016; 22(9): 2760-2770 Published online Mar 7, 2016. doi: 10.3748/wjg.v22.i9.2760
Life and death at the mucosal-luminal interface: New perspectives on human intestinal ischemia-reperfusion
Joep Grootjans, Kaatje Lenaerts, Wim A Buurman, Cornelis H C Dejong, Joep P M Derikx
Joep Grootjans, Kaatje Lenaerts, Cornelis HC Dejong, Joep PM Derikx, Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
Joep Grootjans, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, United States
Wim A Buurman, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 MD Maastricht, The Netherlands
Author contributions: Grootjans J and Derikx JPM wrote the manuscript; Grootjans J, Lenaerts K, Buurman WA, Dejong CHC and Derikx JPM provided important intellectual contribution to the manuscript.
Supported by Dutch Gastroenterology and Hepatology Society (MLDS grant WO10-57 to Dejong CHC and Lenaerts K); Career Development Grant CDG (to Derikx JPM); and The Netherlands Organisation for Scientific Research (Rubicon grant 825.13.012 to Grootjans J).
Conflict-of-interest statement: No conflicts of interest exist.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Joep Grootjans, MD, PhD, Department of Surgery, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, 6200 Maastricht, The Netherlands. j.grootjans@maastrichtuniversity.nl
Telephone: +31-43-3881497 Fax: +31-43-3884154
Received: June 22, 2015 Peer-review started: June 25, 2015 First decision: July 14, 2015 Revised: September 24, 2015 Accepted: December 14, 2015 Article in press: December 14, 2015 Published online: March 7, 2016
Abstract
Intestinal ischemia is a frequently observed phenomenon. Morbidity and mortality rates are extraordinarily high and did not improve over the past decades. This is in part attributable to limited knowledge on the pathophysiology of intestinal ischemia-reperfusion (IR) in man, the paucity in preventive and/or therapeutic options and the lack of early diagnostic markers for intestinal ischemia. To improve our knowledge and solve clinically important questions regarding intestinal IR, we developed a human experimental intestinal IR model. With this model, we were able to gain insight into the mechanisms that allow the human gut to withstand short periods of IR without the development of severe inflammatory responses. The purpose of this review is to overview the most relevant recent advances in our understanding of the pathophysiology of human intestinal IR, as well as the (potential) future clinical implications.
Core tip: To improve our knowledge on the pathophysiology of human intestinal ischemia-reperfusion (IR), a new human experimental model was developed in recent years. In the current review, we overview and discuss the most important new insights on intestinal IR in man.
